Zevra Therapeutics (ZVRA) Treasury Shares (2021 - 2026)

Zevra Therapeutics has reported Treasury Shares for 6 years, with the latest figure at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares changed 0.0% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (changed 0.0% YoY), and the FY2025 full-year result was $11.0 million, changed 0.0% from the prior year.
• Treasury Shares for Q1 2026 stood at $11.0 million, roughly flat from $11.0 million in the prior quarter.
• The five-year high for Treasury Shares was $1.8 million in Q4 2024, with the low at $320161.0 in Q4 2021.
• Historically, Treasury Shares has averaged $1.0 million across 5 years, with a median of $909953.0 in 2022.
• Annual changes were most pronounced in 2022 — Treasury Shares soared 167.8% — and 2024, when it changed 0.0%.
• Zevra Therapeutics' Treasury Shares stood at $7.5 million in 2022, then soared by 45.74% to $11.0 million in 2023, then changed by 0.0% to $11.0 million in 2024, then changed by 0.0% to $11.0 million in 2025, then changed by 0.0% to $11.0 million in 2026.
• The last three Treasury Shares figures came in at $11.0 million (Q1 2026), $11.0 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.